AVIR
Atea Pharmaceuticals Inc
5.20$
+0.0%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 17 | Q1 18 | Q2 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | – | – | – | – | – | – | – | – | – | – | 100.0% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | 28.5% | 40.3% | 65.9% | 131.1% | 30.1% | – | – | – | – | – | – | – | – | – | – | – | 25.0% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | 71.5% | 59.7% | 34.1% | -31.1% | 69.9% | – | – | – | – | – | – | – | – | – | – | – | -25.0% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | 28.5% | 40.3% | 65.9% | 131.1% | 30.1% | – | – | – | – | – | – | – | – | – | – | – | 6,170.9% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | 29.1% | 13.3% | 19.7% | 36.4% | 6.9% | – | – | – | – | – | – | – | – | – | – | – | 3,210.3% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | 29.1% | 13.3% | 19.7% | 36.4% | 6.9% | – | – | – | – | – | – | – | – | – | – | – | 9,356.3% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | 42.5% | 46.5% | 14.4% | -67.5% | 63.1% | – | – | – | – | – | – | – | – | – | – | – | -9,381.3% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | 42.5% | 46.5% | 14.5% | -67.3% | 63.1% | – | – | – | – | – | – | – | – | – | – | – | -8,009.1% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 11.9% | 18.6% | 2.1% | – | – | – | – | – | – | – | – | – | – | – | 54.1% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | 42.5% | 46.5% | 2.5% | -85.9% | 60.9% | – | – | – | – | – | – | – | – | – | – | – | -8,063.2% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | 42.5% | 46.5% | 14.5% | -67.3% | 63.1% | – | – | – | – | – | – | – | – | – | – | – | -7,984.1% | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.